Connect with us

Cannabis News

Most Americans Back Legalizing Marijuana, But Trump Voters Not On Board, Conservative Group’s Poll Shows Amid Rescheduling Rumors

Published

4 months ago

on

As President Donald Trump prepares to announce his decision on rescheduling marijuana, a new poll from a religiously conservative research firm again shows that a majority of Americans are ready to fully legalize cannabis. Trump voters, however, are not on board with the change, except for the younger ones.

The survey — conducted by YouGov on behalf of the Ethics and Public Policy Center (EPPC) — was detailed in a post last week on its Family Matters blog by one of the organization’s senior researchers. Overall, 57 percent of respondents found that they “somewhat” or “strongly” support the legalization of cannabis.

The demographic breakdown of age and political affiliation showed familiar divisions on the issue, with a majority (53 percent) of those over 46 who voted for Trump in the last election opposing legalization. However, 49 percent of Trump voters aged 18-45 say they support reform.

Among people who voted for former Vice President Kamala Harris in the last election, however, there was an unusual finding: more people in the older cohort (87%) said they support legalization than the younger group (71%).

When asked about the net impact of legalization on society, 68 percent of younger Harris voters said the social benefits outweigh the costs, and an even greater majority (82 percent) of older Harris voters said the same.

By contrast, majorities of young and older Trump voters (59 percent and 67 percent, respectively) said legalization is associated with “more social costs than benefits.”

Adults aged 18-45 without children were more than 60 percent in favor of ending the ban, compared to 52 percent who are parents, the poll found.

“This provides the blueprint for a new political coalition interested in curbing the abuses of our fast-track entry into the widespread world of medical marijuana,” said EPPC’s Patrick Brown. he saidand if the Trump administration moves to reschedule marijuana, “conservatives and well-intentioned liberals should not accept a new reality of capitalism-driven marijuana availability without a fight.”

“Concerns about widespread weed’s potential for children’s health — and the long-term outcomes of young adults — will not go away, regardless of the profit motive involved,” he said.

While this poll shows a partisan divide on the issue with most Republicans opposed to legalization, other independent polls in recent years have indicated that ending prohibition is an increasingly bipartisan issue. That being said, Support among GOP voters has fallen slightly over the past year, according to a recent Gallup poll.

A separate research firm associated with the Trump poll of registered voters recently showed this A majority of Republicans support various cannabis reformsincluding rescheduling, states’ rights to legalize and the marijuana industry’s access to banking services and stock exchanges.

Sources familiar with the decision the administration may make on marijuana reform have not suggested the president wants to. legalize marijuana, though. The proposal to move cannabis from Schedule I to III of the Controlled Substances Act (CSA) would mean that it would still be prohibited. But marijuana companies could begin taking federal tax deductions, which could help reduce some research barriers related to Schedule I drugs.

Also announced this week was the president’s executive order on the planned rescheduling It may also include additional components on banking access for cannabis businesses and Medicare coverage for CBD.

on monday Trump said he is “very hard” considering rescheduling cannabis in part, to ease the restrictions on research on its effects.

Those against policy change have it he increased his efforts to prevent the administration from continuingArguing that reclassification to Schedule III will further normalize the use of marijuana, even though the plant has not been federally legalized. The rescheduling, however, would allow marijuana companies to take federal tax deductions while reducing some of the research barriers associated with Decision I drugs.

Rep. Andy Harris (R-MD), one of the most vocal prohibitionists in Congress, said this week Trump has no authority to unilaterally reschedule marijuana by executive order. But while lawmakers could overturn any administrative move to enact reform, he acknowledged it would be a “huge increase” in the Republican-controlled Congress.

Meanwhile, they are the top Democrats in Congress saying that the modest reform would not go far enough– including Sen. Ron Wyden (R-OR), who said the move is nothing more than an attempt by the president to “gaslight” voters into thinking he legalized cannabis to boost his “pathetic” approval ratings.

A major organization in the drug testing industry said this separately Amid reports of “sounding the alarm” Trump may soon end the reorganization proposalthat the policy change would have “catastrophic consequences for the safety of US workers and the transportation sector.”

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

or for what it’s worth, a White House spokesperson told Marijuana Moment last week that no action has been taken so far.

They have been members of Congress in bipartisanship weighing a possible decision to reorganize last week—Democrats like Rep. Alex Ocasio-Cortez (D-NY) call the reform a “no” and others like Rep. Andy Harris (R-MD) have pushed back against the proposal.

The Washington Post reported last week that Trump planned to issue an executive order to federal agencies to move forward with cannabis rescheduling.

The outlet also said the president met with marijuana industry executives Robert F. Kennedy Jr. earlier this week in the Oval Office. with Secretary of Health and Human Services and Centers for Medicare and Medicaid Services Administrator Mehmet Oz. During that meeting, Trump called Johnson, the House Speaker, who opposed the rescheduling of cannabis,

If the administration ultimately enacts the rescheduling, it would mark one of the most significant developments in federal marijuana policy since its prohibition half a century ago, when it was banned under Article III. With a reclassification, marijuana has medical value and a lower abuse potential compared to Schedule I drugs like heroin.

Mike Latimer’s photo.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Related Topics:
Continue Reading

Cannabis News

Critical updates for cannabis taxpayers as the 2025 filing deadline approaches

Published

9 hours ago

on

April 5, 2026

By











With the April 2025 tax return filing deadline fast approaching, cannabis companies must once again face the burden of Section 280E of the Internal Revenue Code (“Section 280E”). Despite significant developments over the past year — including a major executive order from President Trump and the IRS, for the first time, disclosing legal reasoning funds to keep state cannabis “within the meaning” of Section 280E — taxpayer scrutiny remains the same.

However, whether substantively or psychologically, these recent developments weigh on how taxpayers should deal with Section 280E. Below, we summarize the key developments that cannabis taxpayers should be aware of as they prepare their 2025 returns.

As discussed in previous publications, Section 280E provides: “(e) no deduction or credit shall be allowed for any amount paid or incurred in the course of any trade or business during the taxable year, if such trade or business (or the activities constituting such trade or business) is trafficking in controlled substances (controlled substance classes I and II prohibited by State or Federal law).

Because cannabis is now listed as a Schedule I controlled substance under the Controlled Substances Act (CSA), the IRS has consistently maintained that Section 280E applies to state-licensed cannabis businesses, significantly increasing their effective tax rates.

Read more at JD above










Continue Reading

Cannabis News

Louisiana Senators Approve Bill To Allow Medical Marijuana Use In Hospitals For Terminally Ill Patients

Published

9 hours ago

on

April 5, 2026

By

A Louisiana Senate panel has advanced a bill to allow patients with terminal and irreversible conditions to use medical marijuana in hospitals.

The Senate Health and Welfare Committee approved the legislation, SB 270 (D) by Sen. Katrina Jackson-Andrews, with amendments, on a voice vote Wednesday.

“This bill was introduced at the request of voters who believe that therapeutic medical marijuana, which is already legal in this state, should be offered in hospitals when the terminally ill or otherwise need the comfort of this medicine,” Jackson-Andrews said before the vote.

Under the proposal, hospitals would have to create written policies to allow covered patients to consume medical cannabis in forms other than smoking or vaporizing it.

Under an amendment approved by the panel, emergency or outpatient departments would be exempt from the policy. The revised legislation also clarifies that patients and primary caregivers are responsible for obtaining and administering medical marijuana, which “must be securely stored at all times in a sealed container provided by the patient.”

Health care professionals and staff would be prohibited from “administering, storing, retrieving, or assisting a patient with medical marijuana.” the text he says

The amendment, which the proponent worked out with the help of the Louisiana Hospital Association, also allows hospitals to opt out of the policy if federal officials take action against any health care facility in the state regarding the use of medical cannabis, instead of allowing those specifically targeted to stop serving.

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

Meanwhile, in Louisiana, the Senate Health and Welfare Committee passed a bill last week create a pilot psychedelic-assisted therapy program using opioid settlement dollars to fund clinical trials to develop alternative treatments such as psilocybin and ibogaine.

Lawmakers are also considering a bill creating a pilot program to legalize marijuana for adults in the state, in the end, to determine whether the reform should be expanded and permanently codified.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Continue Reading

Cannabis News

Cresco Labs gets Texas license

Published

1 day ago

on

April 4, 2026

By











Cresco Labs has obtained a Texas Compassionate Use Program License. It is a vertically integrated license that allows Cresco Labs to cultivate, process and distribute medical cannabis.

“Texas patients deserve access to consistent, quality medicine, and we’re excited. Our track record in medical markets reflects our ability to build strong programs that put patients and communities first,” said Charlie Bachtell, CEO of Cresco Labs. “Winning a license in Texas through a merit-based application demonstrates Cresco Labs’ deep regulatory expertise and thoughtful approach to meaningful local engagement. Organic licenses enable capital-efficient market entry, and our cash flow and balance sheet give us the financial flexibility to invest in and grow our scaled platform for the long term.”

This license advances Cresco Labs’ state-by-state growth strategy and ensures access to one of the largest patient populations in the United States. Texas is the nation’s second most populous state, approaching 30 million people, and continues to see ongoing legislative efforts to improve patient access and expand eligibility.










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media